Journal article
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial
WK Huh, EA Joura, AR Giuliano, OE Iversen, RP de Andrade, KA Ault, D Bartholomew, RM Cestero, EN Fedrizzi, AL Hirschberg, MH Mayrand, AM Ruiz-Sternberg, JT Stapleton, DJ Wiley, A Ferenczy, R Kurman, BM Ronnett, MH Stoler, J Cuzick, SM Garland Show all
Lancet | Published : 2017
Abstract
Background Primary analyses of a study in young women aged 16–26 years showed efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58) vaccine against infections and disease related to HPV 31, 33, 45, 52, and 58, and non-inferior HPV 6, 11, 16, and 18 antibody responses when compared with quadrivalent HPV (qHPV; HPV 6, 11, 16, and 18) vaccine. We aimed to report efficacy of the 9vHPV vaccine for up to 6 years following first administration and antibody responses over 5 years. Methods We undertook this randomised, double-blind, efficacy, immunogenicity, and safety study of the 9vHPV vaccine study at 105 study sites in 18 countries. Women aged 16–26 y..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
Merck & Co, Inc.